Episode Details
Back to Episodes
Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond
Episode 6
Published 5 years, 8 months ago
Description
In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:
- FLT3 inhibitors crenolanib and quizartinib
- Anti-CD47 antibody magrolimab
- IMGN632, a CD123 antibody–drug conjugate
- Anti-CD70 antibody cusatuzumab
- APR-246, targeting the TP53 mutation
Content is part of an online CME program supported by an educational grant from Daiichi-Sankyo.
Link to full program, including a ClinicalThought commentary: https://bit.ly/2Y2uCG2
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.